液体活检在转移性前列腺癌临床管理中的整合。
Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer.
机构信息
Division of Medical Oncology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
出版信息
Curr Oncol Rep. 2022 Oct;24(10):1287-1298. doi: 10.1007/s11912-022-01278-0. Epub 2022 May 16.
PURPOSE OF REVIEW
The field of liquid biopsies is constantly evolving through novel technologies. This review outlines current data on liquid biopsies and application to clinical management of metastatic prostate cancer.
RECENT FINDINGS
To date, there are three platforms with FDA approval for use in the setting of metastatic prostate cancer and others which have been clinically validated. There is substantial evidence supporting the use of circulating tumor cell (CTC) enumeration to guide prognosis in metastatic castration-resistant prostate cancer (mCRPC). Additional evidence supports targeted sequencing of CTC and cell-free DNA (cfDNA) to guide androgren-directed therapy, identify candidates for treatment with PARP inhibitors, and monitor development of resistance. As a real-time and minimally invasive approach, utilization of liquid biopsies has the potential to drastically impact the treatment of metastatic prostate cancer and improve overall survival. With further clinical validation, additional liquid biopsy is likely to enter standard clinical practice.
目的综述
液体活检领域正通过新技术不断发展。本文概述了液体活检的最新数据及其在转移性前列腺癌临床管理中的应用。
最近的发现
迄今为止，有三个获得 FDA 批准用于转移性前列腺癌的平台，还有其他一些已在临床上得到验证。有大量证据支持使用循环肿瘤细胞 (CTC) 计数来指导转移性去势抵抗性前列腺癌 (mCRPC) 的预后。额外的证据支持对 CTC 和无细胞 DNA (cfDNA) 进行靶向测序，以指导雄激素靶向治疗，确定 PARP 抑制剂治疗的候选者，并监测耐药性的发展。作为一种实时和微创的方法，液体活检的应用有可能极大地影响转移性前列腺癌的治疗并改善总体生存率。随着进一步的临床验证，更多的液体活检可能会纳入标准的临床实践。
Zotero 插件